Specialty Drug Spend: Cost Savings for Self-Funded Portfolio Companies

05/25/2023 Written by: Thomas Rosenbaum

Employer-sponsored health plans continue to face increasing costs due to the rising price of medical procedures, prescription drugs, and administrative services in the broader health insurance industry. However, employers with self-funded health plans can reduce costs by influencing how and where their plan members consume healthcare goods and services.

A growing cost burden for employer-sponsored health plans is specialty medications. These high-cost drugs are often used to treat chronic conditions such as cancer, multiple sclerosis, and rheumatoid arthritis. Cost variance is also high, depending on where these drugs are procured and administered. Hospitals that administer specialty medications charge 118% more than specialty pharmacies for the same medication.

Exhibit 1: The variance in cost is extreme in the outpatient hospital setting for Ocrevus (and many similar infusible drugs). 1200mg of Ocrevus ranged from $70,600 to $196,500 for the 10th and 90th percentiles.

This cost variance presents self-funded employers with an opportunity. Employers can drastically reduce the cost of their healthcare claims by ensuring they pay the lowest possible price for these drugs through “white bagging.” White bagging is a practice in which a specialty pharmacy ships a patient's prescription directly to the provider, such as a hospital or a physician's office. The specialty pharmacy bills the health plan at a much lower cost than the hospital would have billed if it had purchased the medication directly from the drug manufacturer.

The above table shows actual claims from an AP client who had an employee receiving an Ocrevus infusion at the hospital for ~$250,000 every six months. White bagging this drug reduced the cost paid by the employer to $35,000. This strategy led to an annualized cost reduction of $430,000 per year.

M&A Blog Image
Understanding Successor Liability in Asset Purchases: Key Areas to Watch Out For
Mergers & Acquisitions Insurance11/13/2023

Do I need to be concerned about successor liability if I’ve structured my transaction as an asset purchase? Several factors can drive the decision to structure a transaction as a pure asset...

How Is Insurance Due Diligence Different From A Coverage Review?
Mergers & Acquisitions Insurance09/26/2023

It is common practice for insurance brokers to provide a client or prospective client coverage reviews of a target Company’s insurance program. The reviews are beneficial from a risk management...

M&A Risk Insights: Cyber Liability
Mergers & Acquisitions Insurance03/07/2023

Companies that historically viewed cyber liability insurance as merely a “nice to have” component of their risk management strategy are learning that the coverage has now become a “must have” if they...